Sugi Predict

Sugi Predict / Compounds / SCHEMBL758293

SCHEMBL758293

SCHEMBL758293

COP(=O)(CC(=O)Cc1ccccc1)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.47
▸ POLB P06746 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ CES2 O00748 1/20 0.45
▸ CES1 P23141 1/20 0.45
▸ AKR1B1 P15121 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ PAM P19021 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ LAP3 P28838 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ PLAU P00749 1/20 0.41
▸ ELANE P08246 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11814078 0.90 GAA (0.51) TSHRLMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL4912040 0.86 GGPS1 (0.43) AKR1B1
SCHEMBL10812724 0.84 L3MBTL1 (0.46) LMNAALDH1A1L3MBTL1TDP1MAPT
SCHEMBL4993496 0.84 FDFT1 (0.50) HDAC8
SCHEMBL3970824 0.83 HTT (0.53) POLBALDH1A1L3MBTL1KDM4ESMN1; SMN2
SCHEMBL1401007 0.83 HTT (0.43) POLBLMNAMAPK1KDM4ESMN1; SMN2
SCHEMBL2322779 0.83 ALDH1A1 (0.47) TSHRPOLBALDH1A1L3MBTL1KDM4E
SCHEMBL6915874 0.83 MAPK1 (0.48) TSHRPOLBALDH1A1L3MBTL1MAPK1
SCHEMBL187684 0.83 ALOX5 (0.51) POLBLMNAALDH1A1L3MBTL1KDM4E
SCHEMBL6264197 0.82 CTBP2 (0.47) POLBALDH1A1L3MBTL1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 — — US disclosed
US-10941109-B2 Compositions and methods of treatment using a BCAT1 inhibitor ERGON PHARMACEUTICALS LLC (US) 2021-03-09 — — US disclosed
US-20160368862-A1 COMPOSITIONS AND METHODS OF TREATMENT USING A BCAT1 INHIBITOR Ergon Pharmaceuticals, LLC (US) 2016-12-22 — — US disclosed
US-20160368862-A1 COMPOSITIONS AND METHODS OF TREATMENT USING A BCAT1 INHIBITOR Ergon Pharmaceuticals, LLC (US) 2016-12-22 — — US disclosed
EP-1631355-B1 PIPERIDINYL PROSTAGLANDIN E ANALOGS ALLERGAN INC (US) 2014-08-13 — — EP disclosed
US-20130317013-A1 EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF BILLOT XAVIER (CA) 2013-11-28 — — US disclosed
EP-1503984-B1 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN INC (US) 2013-03-20 — — EP disclosed
EP-1761495-B1 PIPERIDINYL PROSTAGLANDIN ANALOGS AS OCULAR HYPOTENSIVE AGENTS ALLERGAN INC (US) 2012-03-21 — — EP disclosed
US-20110237511-A1 EP4 Receptor Agonist, Compositions and Methods Thereof MERCK FROSST CANADA (CA) 2011-09-29 — — US disclosed
US-RE42562-E1 EP4 receptor agonist, compositions and methods thereof MERCK FROSST CANADA (CA) 2011-07-19 — — US disclosed
US-4029814-A ANTIULCER, ANTICOAGULANT, DECONGESTANT, OXYTOCIC THE UPJOHN COMPANY (US) 1977-06-14 — — US disclosed
US-4018892-A Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters PFIZER INC. (US) 1977-04-19 — — US disclosed
US-4011262-A 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series PFIZER INC. (US) 1977-03-08 — — US disclosed
US-4000309-A Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters PFIZER INC. (US) 1976-12-28 — — US disclosed
US-3993686-A Phenyl substituted prostaglandins-C-type analogs THE UPJOHN COMPANY (US) 1976-11-23 — — US disclosed
US-3984424-A MEDICAMENTS PFIZER INC. (US) 1976-10-05 — — US disclosed
US-3982016-A Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters PFIZER INC. (US) 1976-09-21 — — US disclosed
US-3971826-A 15-Substituted-ω-pentanorprostaglandins PFIZER INC. (US) 1976-07-27 — — US disclosed
US-3932389-A ANTIULCER AGENTS PFIZER INC. (US) 1976-01-13 — — US disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237511-A1 EP4 Receptor Agonist, Compositions and Methods Thereof PTGER4, PTGER1, PTGER3 TSHR 692/4885POLB 4617/4885LMNA 2765/4885
US-20160368862-A1 COMPOSITIONS AND METHODS OF TREATMENT USING A BCAT1 INHIBITOR BCAT1, TPT1, BCAT2 TSHR 4718/4885POLB 2483/4885LMNA 1852/4885
US-20130317013-A1 EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF PTGER4, PTGER1, PTGER3 TSHR 402/4885POLB 4166/4885LMNA 2379/4885
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME ASNS, SI, NARS1 TSHR 4589/4885POLB 1641/4885LMNA 2652/4885
US-10941109-B2 Compositions and methods of treatment using a BCAT1 inhibitor BCAT1, TPT1, BCAT2 TSHR 4718/4885POLB 2483/4885LMNA 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.